Materiały źródłowe

• #1 Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8934743/

  We aimed to determine the population-based incidence, prevalence, and mortality of dermatomyositis (DM) using European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) criteria. […] The overall adjusted incidence of DM was 1.1 (95% CI 0.7 to 1.5) per 100,000 person-years, and prevalence was 13 (95% CI 6 to 19) per 100,000. […] This population-based study found DM incidence and prevalence were higher than previously reported. Mortality was significantly elevated for myopathic DM but not for CADM. […] The age- and sex-adjusted overall incidence of DM was 1.1 (95% CI 0.7 to 1.5) per 100,000 person-years, corresponding to 2,858 new cases of DM in the United States each year. […] The age- and sex-adjusted overall prevalence of DM on 1/1/2015 was 13 (95% CI 6 to 19) per 100,000, corresponding to 34,061 individuals in the United States.

• #2 Epidemiology of Dermatomyositis | SpringerLink

  https://link.springer.com/chapter/10.1007/978-3-540-79313-7_5

  Dermatomyositis affects both children and adults. The incidence of DM is approximately 1020 times lower than the incidence of lupus erythematosus, or other connective tissue diseases systemic sclerosis or rheumatoid polyarthritis. […] The absence of reliable epidemiologic data for DM is rather surprising and may relate to several reasons: (i) the rarity of disease, (ii) the lack of consistent use of diagnostic criteria, (iii) the indolent clinical course, (iv) the fact that the numbers result from studies on hospitalized patients, (v) the management of outpatients by physicians from many different specialties (including pediatric and adult rheumatologists, neurologists, dermatologists, other specialists, and general practitioners), and (vi) the lack of prospective studies of associated myositis in connective tissue disease.

• #2 Incidence, Prevalence, and Mortality of Dermatomyositis in Adults Determined – Dermatology Advisor

  https://www.dermatologyadvisor.com/home/topics/general-dermatology/incidence-prevalence-and-mortality-of-dermatomyositis-in-adults-determined/

  Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults. […] New estimates of the incidence and prevalence of dermatomyositis (DM) in the US are higher than previously reported, with standard mortality ratios 3 times higher than those in the general population, according to study results published in Arthritis Care Research. […] The current population-based cohort study was conducted to better understand the epidemiology of DM. […] The researchers calculated incidence and prevalence (as of January 1, 2015) that was age- and sex-adjusted to the US, non-Hispanic, White, 2000 population. […] The overall adjusted incidence of DM was 1.1 per 100,000 person-years (95% CI, 0.7-1.5 per 100,000 person-years), which corresponded to 2858 new cases of DM in the US each year. The prevalence of DM was 13 per 100,000 person-years (95% CI, 6-19 per 100,000 person-years), which corresponded to 34,061 individuals in the US with DM.

• #3 Dermatomyositis | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/20389

  Dermatomyositis is a rare condition. A retrospective study conducted between 1967 and 2007 in Olmsted county, Minnesota, estimated an incidence rate of 9.63 per 1,000,000 people. The same study also found that 21% of all cases were of the amyopathic subtype. Dermatomyositis commonly affects persons between the ages of 40 and 50 with a mean age at diagnosis of 44.0 18.3 years. The condition is more common in women than in men, with incidence rates being 3.98 and 4.68 per 1,000,000, respectively. […] In Europe, a higher prevalence of dermatomyositis has been noted in Southern Europe compared to Northern Europe. A study conducted in Quebec showed a higher prevalence of dermatomyositis in urban areas. A cohort study conducted in Pennsylvania also showed clusters of clinically amyopathic dermatomyositis (CADM) in regions with high airborne pollution. These studies point towards the possibility of environmental factors acting as triggers for the condition.

• #4 Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study | Scientific Reports

  https://www.nature.com/articles/s41598-023-43880-7

  Dermatomyositis is a rare disease characterized by progressive muscle weakness and skin rashes. Estimates of incidence and prevalence are fundamental measures in epidemiology, but few studies have been conducted on dermatomyositis. To address this knowledge gap, we conducted a population-based study to determine the contemporary incidence (between 2013 and 2019) and prevalence (2019) of adults living with dermatomyositis using administrative health data in Alberta, Canada. […] The average age- and sex-standardized annual incidence of dermatomyositis was 2.83.0 cases per 100,000 adults, and prevalence was 28.6 cases per 100,000 adults, which is greater than reported in other cohorts. […] Considering that Alberta may have one of the highest rates of dermatomyositis among adults, further research on the burden of disease is warranted for planning within the health care system.

• #5 Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study | Scientific Reports

  https://www.nature.com/articles/s41598-023-43880-7

  The standardized overall average annual incidence was estimated at 2.83.0 cases per 100,000 adults between 2013 and 2019, and standardized prevalence was 28.6 cases per 100,000 adults on March 31, 2019, which is greater than most previous reports. […] Findings from this study provide a contemporary description of the epidemiology and medication use of adults living with DM in Alberta, Canada. […] The reported incidence and prevalence of DM varies widely due to the limited number of studies conducted in this area, the different methodological approaches, and the rare nature of the disease. […] To our knowledge, this study is the first to report the incidence of DM in Canada, and results indicate that incidence among the adult population in Alberta may be higher than the USA, but lower than Norway. […] Considering that Alberta may have one of the highest rates of DM among adults, further research on the burden of disease is warranted for planning within the health care system.

• #6 Orphanet: Dermatomyositis

  https://www.orpha.net/en/disease/detail/221

  A rare idiopathic inflammatory myopathy (IIM) characterized by evocative skin lesions, muscle involvement with symmetrical proximal muscle weakness, and specific histological features. […] Annual incidence is estimated between 1/125,000-1,000,000, and prevalence between 1/10,000-50,000. Dermatomyositis (DM) is more common in women than in men (2:1). […] About one third of DM patients develop malignancy, often within 0 to 3 years before or after disease onset (breast and ovarian cancers in women, and lung and prostate cancer in men).

• #7 Dermatomyositis: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/332783-overview

  The estimated incidence of dermatomyositis is 9.63 cases per million population. The estimated incidence of AMD is 2.08 cases per million. […] Dermatomyositis can occur in people of any age. Two peak ages of onset exist: in adults, the peak age of onset is approximately 50 years, whereas in children, the peak age is approximately 5-10 years. Dermatomyositis and polymyositis are twice as common in women as in men. Neither condition shows any racial predilection.

• #8

  https://www.healio.com/clinical-guidance/dermatomyositis/epidemiology-of-dm

  Dermatomyositis (DM) can occur in adults and children. Incidence of DM in the United States in adults is seen in 15.2/million person-years, with a prevalence of 21.4/100,000 people. […] Adult DM affects women more than men (usually a ratio of 2:1), with incidence rates being 3.98 and 4.68 per 1,000,000 people, respectively. […] The onset of DM manifests in two peak periods, diagnosed in juveniles between ages 4-14 years and in adults between ages 40-60 years. The reported mean age of disease onset is approximately 7 years and 42 years in children and adults, respectively. […] Higher prevalence of DM has been shown in urban areas, regions with higher airborne pollution, suggesting a link with environmental factors. […] About 10% of patients die of DM. The most common causes of death are malignancy and cardiopulmonary complications including inflammatory cardiomyopathy or severe Interstitial lung disease (ILD). Some factors associated with higher mortality and poor outcome are as follows: Advanced age.

• #9

  https://juniperpublishers.com/oroaj/OROAJ.MS.ID.556120.php

  Gender is another important risk factor, as DM disproportionately affects females more than males, with some studies suggesting a female-to-male ratio of up to 2:1. […] Age is also a factor, with peak incidence occurring in adulthood, typically between 40 and 60 years old, although juvenile dermatomyositis affects children and adolescents. […] Also, a family history of autoimmune diseases, such as lupus or rheumatoid arthritis, may increase susceptibility to DM, highlighting a possible shared genetic susceptibility across autoimmune disorders.

• #10 Dermatomyositis/Polymyositis | Select 5-Minute Pediatrics Topics

  https://www.unboundmedicine.com/5minute/view/Select-5-Minute-Pediatric-Consult/14063/all/Dermatomyositis_Polymyositis?q=Dermatomyositis

  The average age of onset is 7 years, but 25% of cases are diagnosed by 4 years of age. […] Male-to-female ratio in the United States is 1:2.3. […] JDM incidence is 3.2 new cases per 1 million children per year; JPM is extremely rare.

• #11 Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations – UpToDate

  https://www.uptodate.com/contents/juvenile-dermatomyositis-and-other-idiopathic-inflammatory-myopathies-epidemiology-pathogenesis-and-clinical-manifestations

  Juvenile dermatomyositis (JDM) is the most common form of the rare idiopathic inflammatory myopathies (IIM; also called autoimmune or immune-mediated myopathies) affecting children. JDM is characterized by symmetric, proximal muscle weakness and distinct rashes including eyelid heliotrope dermatitis and Gottron papules. The epidemiology, pathogenesis, and clinical manifestations of JDM and other IIM are reviewed here. […] JDM is the most common IIM of childhood, accounting for approximately 85 percent of cases. In population-based studies, JDM has a reported annual incidence that ranges from two to four cases per one million children and a prevalence of approximately 4 per 100,000. The peak incidence is from 5 to 10 years of age. Females are affected more often than males, with a two- to fivefold greater rate. […] JPM occurs less frequently and accounts for only 3 to 6 percent of childhood IIM.

• #12 Dermatomyositis: what the oral healthcare provider must know | Journal of Oral Medicine and Oral Surgery

  https://www.jomos.org/articles/mbcb/full_html/2021/01/mbcb200068/mbcb200068.html

  The rarity of the condition has lead to limited information on its incidence and prevalence. The reported incidence in literature is 9.63 cases per million persons, while clinically amyopathic DM (ADM) is estimated to be 2.08 cases per million. DM exhibits a bimodal age distribution of children under 18 years (juvenile DM, JDM) and adults in their late 40s to early 60s. There is a female predominance over males with a ratio of 1.52.0:1; however, in older patients with malignancy, there is an equal sex ratio. Diagnosis is generally made at an average age of 40 years, while malignancy is commonly observed at an average age of 55 years. DM associated with a connective tissue disease is predominantly observed among younger women with a higher prevalence in African-Americans. […] Adult DM patients have exhibited an increased risk of development of malignancy, an observation that has made early diagnosis, treatment and continual monitoring crucial.

• #13 Dermatomyositis Epidemiology Forecast Report 2034

  https://www.globenewswire.com/news-release/2024/12/18/2999161/28124/en/Dermatomyositis-Epidemiology-Forecast-Report-2034.html

  The „Dermatomyositis – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Dermatomyositis, historical and forecasted epidemiology of Dermatomyositis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. […] The total diagnosed prevalent cases of Dermatomyositis in the United States were around 38.5 thousand cases in 2023. […] The United States contributed to the largest diagnosed prevalent population of Dermatomyositis, acquiring ~54% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 29% and 17% of the total population share, respectively, in 2023. […] According to estimates, in 2023, there were nearly 72 thousand total diagnosed prevalent cases of dermatomyositis in the 7MM, of which nearly 9% were juvenile and 91% were adult.

• #14 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  The epidemiology of idiopathic inflammatory myopathies (IIMs) varies by country. […] We aimed to assess the prevalence and incidence of IIM in the Thai population between 2017 and 2020. […] The prevalence and incidence of IIMs were analyzed with their 95% confidence intervals (CIs) and then categorized by sex and region. […] In 2017, the IIM cases numbered 9,074 among 65,204,797 Thais, resulting in a prevalence of 13.9 per 100,000 population (95% CI 13.6-14.2). […] IIMs were slightly more prevalent among women than men (16.8 vs 10.9 per 100,000). […] Between 2018 and 2020, the incidence of IIMs slightly declined from 5.09 (95% CI 4.9-5.27) in 2017 and 4.92 (95% CI 4.76-5.10) in 2019 to 4.43 (95% CI 4.27-4.60) per 100,000 person-years in 2020. […] The peak age group was 50-69 years.

• #15 Incidence and prevalence of idiopathic inflammatory myopathies in Thailand from the Ministry of Public Health data analysis | Scientific Reports

  https://www.nature.com/articles/s41598-024-71633-7

  Between 2018 and 2020, the majority of cases occurred in southern Thailand, with incidence rates of 7.60, 8.34, and 8.74 per 100,000 person-years. […] The incidence of IIMs decreased between 2019 and 2020, most likely due to the COVID-19 pandemic, which reduced reports and investigations. […] The current study determined that the prevalence of IIMs among Thais was similar to that of the majority of IIMs worldwide, with a rate of 13.93 per 100,000 (95 percent CI 13.6-14.21) in 2017. […] Our study reveals a decline in the incidence of IIMs among Thais from 2017 to 2020. […] Female cases predominate among IIMs in Thailand, which is consistent with previous research. […] Our research revealed that the peak prevalence of IIMs occurs between 60 and 69 years. […] The presence of IIMs in Thailand is unusual. It peaks among people aged 60 to 69, especially in southern Thailand. […] Furthermore, the frequency of IIM cases decreased significantly between 2019 and 2020, which was most likely influenced by the COVID-19 pandemic.

• #16 THU0622 Epidemiology and Outcome of Dermatomyositis in Northwestern Thrace Region in Turkey | Annals of the Rheumatic Diseases

  https://ard.bmj.com/content/75/Suppl_2/418.2

  Dermatomyositis (DM) is a rare disease that may affect the skeletal muscles and the skin. Literature data on its incidence and prevalence are limited. There is no data on its incidence or prevalence in Turkey. […] In our study, we determined the epidemiology, general clinical features and outcomes of DM based on hospital-based data in Thrace region, which is in northwestern Turkey. […] Our study included 23 patients with dermatomyositis. Of them, 14 (60.9%) were females and 9 (39.1%) were males (female to male ratio: 1.55). Over the course of the study, the annual incidence of dermatomyositis was 3.7/1,000,000 (95%CI: 018.8); and the overall prevalence was 32.2/1,000,000 (95%CI: 18.146.3). Incidence in women was higher 4.6/1,000,000 (95%CI: 028.6) compared to men 2.9/1,000,000 (95%CI: 021.6). […] In conclusion, in our hospital-based study on DM for which very limited epidemiological data is available, we observed lower frequency than in North American studies. Female gender was more common in our series. Data in this study is the first epidemiological data on DM reported from Turkey.

• #17 :: JKMS :: Journal of Korean Medical Science

  https://jkms.org/DOIx.php?id=10.3346/jkms.2019.34.e55

  Using a nationwide population-based database that included most of the Korean population, we estimated an overall IIM prevalence rate of 2.34.4/100,000 persons and an incidence of 2.95.2 per 1,000,000. We did not observe any trends in incidence over a 10-year period. […] Our calculated prevalence and incidence were lower than those reported in a recent study from Sweden between 2007 and 2011 (prevalence of 14/100,000 and incidence of 11/1,000,000) and a meta-analysis of prevalence (14/100,000 between 1982 and 2010 and incidence 7.98/1,000,000 between 1951 and 2010). […] In conclusion, our study observed a slightly lower prevalence and incidence of IIM in Korea compared to recent reports from other countries. More than two-thirds of patients had more than two comorbidities.

• #18 Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study

  https://pmc.ncbi.nlm.nih.gov/articles/PMC8934743/

  The standardized mortality ratio among the myopathic DM cases was significantly elevated at 3.1 (95% CI 1.1 to 6.8). The mortality of the CADM cases was not statistically significantly elevated at 1.1, though the confidence interval was wide (95% CI 0.2 to 3.3). […] This population-based cohort study established the incidence, prevalence, and mortality of dermatomyositis using validated DM criteria.

• #19 Incidence, Prevalence, and Mortality of Dermatomyositis in Adults Determined – Dermatology Advisor

  https://www.dermatologyadvisor.com/home/topics/general-dermatology/incidence-prevalence-and-mortality-of-dermatomyositis-in-adults-determined/

  The standardized mortality ratio was significantly higher than expected for individuals with DM (3.1; 95% CI, 1.1-6.8), but not for those with clinically amyopathic DM (1.1; 95% CI, 0.2-3.3). […] The researchers concluded, This population-based study using validated DM criteria found incidence and prevalence on the higher end of previous reports, and mortality of myopathic DM significantly elevated compared to peers. Future, larger studies of validated DM cases should examine incidence and mortality over time and causes of death to better understand disease pathogenesis and treatment.

• #20 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The 5-year survival rate for polymyositis is 75% and for dermatomyositis is 63%. […] The median survival for polymyositis is 11.0 years and that for dermatomyositis is 12.3 years. […] Dermatomyositis has a bimodal pattern, commonly affects both children and adults over 50 years old. […] Polymyositis commonly affects adults after second decades of their lives and it is rare among children. […] There is no racial predilection to polymyositis and dermatomyositis. […] The female to male ratio is approximately 2 to 1. […] Prevalence of polymyositis and dermatomyositis are lower in young rural men and higher in older urban women.

• #20 Polymyositis and dermatomyositis epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Polymyositis_and_dermatomyositis_epidemiology_and_demographics

  The incidence of polymyositis and dermatomyositis is approximately 1-5 per 100,000 individuals worldwide. The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] The incidence of polymyositis and dermatomyositis is approximately 2 per 100,000 individuals worldwide. […] In 2010, the incidence of polymyositis and dermatomyositis was estimated to be 1-1.3 cases per 100,000 individuals in Japan annually. […] The prevalence of polymyositis and dermatomyositis is approximately 5-22 per 100,000 individuals worldwide. […] In 2003, the prevalence of polymyositis and dermatomyositis was estimated to be 21.5 cases per 100,000 individuals in Quebec. […] In 2010, the prevalence of polymyositis and dermatomyositis was estimated to be 13.2 cases per 100,000 individuals in Japan.

• #21 Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan | The Journal of Rheumatology

  https://www.jrheum.org/content/51/12/1262

  In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM). […] Subsequently, Kuwana et al reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD. […] As the maximum 3-year surveillance period has been completed, we now report the safety and efficacy results beyond 2 years to further highlight the long-term clinical utility of tacrolimus in these patients. […] The overall survival (OS) rate remained consistent from 2 to 3 years (90% vs 89%). […] The progression-free survival (PFS) rate decreased from 63% at 2 years to 51% at 3 years. […] The decrease in PFS from 2 to 3 years further highlights the need for the close monitoring of these patients even though they are receiving ongoing treatment.

• #22 Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan | The Journal of Rheumatology

  https://www.jrheum.org/content/51/12/1262

  Overall, from 2 to 3 years, mean serum ferritin, Krebs von den Lungen 6, and surfactant protein D levels remained broadly consistent, whereas percent forced vital capacity decreased somewhat between timepoints. […] Overall, there were no new safety concerns with the use of tacrolimus-containing immunosuppressive regimens at 3 years of follow-up. […] In conclusion, the final 3-year surveillance results of this study were in line with the previously reported 2-year interim report and provide additional evidence for the continued long-term use of tacrolimus-containing immunosuppressive regimens in real-world clinical practice in patients with PM/DM-associated ILD.

• #23 SciELO Brazil – Diagnosis of dermatomyositis and polymyositis: a study of 102 cases Diagnosis of dermatomyositis and polymyositis: a study of 102 cases

  https://www.scielo.br/j/anp/a/XD5DvsTjhyMY6pJCgxMxvbs/

  The incidence of PM, DM and inclusion-body myositis is approximately 1 in 100,000. […] The critical tests for establishing and confirming the diagnosis of polymyositis or dermatomyositis are measurement of serum muscle enzymes, electromyography, and muscle biopsy. […] The objective of the present study is to acquire information on clinical signs and symptoms, laboratory features, electromyographies and muscle biopsies from patients with IIM comparing them with the literature with a view to seeking differences between DM and PM. […] We found 9% of cases in association with connective-tissue diseases (CTD), mainly among patients with DM. […] We found only 5% of cases associated with malignancy. […] The mean value of ESR was significantly higher in patients with dermatomyositis, and it could represent, as previously mentioned, a more intense systemic repercussion in DM than in PM.

• #24 Dermatomyositis Epidemiology Forecast Report 2034

  https://www.globenewswire.com/news-release/2024/12/18/2999161/28124/en/Dermatomyositis-Epidemiology-Forecast-Report-2034.html

  As per estimates, Japan accounted for nearly 17% of the Total Diagnosed Prevalent Cases of Dermatomyositis in the 7MM in 2023. […] In 2023, analysis of the chronicity-specific data in the US revealed that 70% of people affected with Dermatomyositis have Chronic type, while 30% have the Acute Type. […] In Japan in 2023, comorbidity-specific cases accounted for the following percentages of diagnosed prevalent cases: ILD at 20%, CVD at 18%, cancer malignancy at 4%, and other conditions (including osteoporosis, dysphagia, Raynaud’s syndrome, calcinosis, etc.) at 58%.

• #25 Environmental triggers of dermatomyositis: a narrative review

  https://atm.amegroups.org/article/view/49740/html

  In genetically susceptible individuals, viral, bacterial, and parasitic infections have been suspected to induce autoimmunity and even exacerbate existing autoimmune conditions. […] Epidemiological data shows that subsets of polymyositis (PM) and DM patients defined by various myositis-specific antibodies tend to develop disease at specific times of the year. […] The relationship of infection to DM onset has been better evaluated in children. […] Although infection as a trigger has been heavily studied in JDM, infections have also been shown to play a role in adult DM onset. […] The prevalence of DM increases significantly with decreasing geographical latitude from northern Europe to southern Europe, suggesting that UV exposure may be implicated in DM pathogenesis. […] It is well established that increased particulate matter in the air, such as from vehicle and industrial emissions, is associated with increased mortality.

• #26 Dermatomyositis following COVID-19 vaccination | HKMJ

  https://www.hkmj.org/abstracts/v31n1/74.htm

  Dermatomyositis, inflammatory myopathy, and rheumatic immune-mediated inflammatory diseases have been reported following COVID-19 vaccination and infection. […] In a systematic review up to May 2023, 24 cases of post-COVID-19 vaccination dermatomyositis were reported worldwide, the majority following vaccination with Pfizer-BioNTech vaccine, and some following that with Moderna and Oxford-AstraZeneca vaccines. […] The close temporal sequence and surge against a background of the reported case series suggest an association between severe acute respiratory syndrome coronavirus 2 infection/vaccination and the development of dermatomyositis, although proof of causality requires further research because of the limited number of cases reported. […] The COVID-19 vaccination and infection may trigger a proinflammatory immune response involving type I interferon and stimulate production of dermatomyositis-specific autoantibodies such as MDA5 that are closely related to viral defence or viral RNA interaction supporting the concept of infection and vaccination-associated dermatomyositis.

• #27 Dermatomyositis following COVID-19 vaccination | HKMJ

  https://www.hkmj.org/abstracts/v31n1/74.htm

  This case demonstrates that dermatomyositis can be induced by COVID-19 vaccination, ignorance of which and of the diagnostic clinical signs would lead to delayed diagnosis and management. […] When patients present with constitutional symptoms with persistent muscle aches and weakness following COVID-19 vaccination, clinicians should consider dermatomyositis as a differential diagnosis and examine the skin for pathognomonic signs.

• #28 Navigating the Challenges in Dermatomyositis Treatment

  https://www.delveinsight.com/blog/dermatomyositis-treatment-outlook

  Dermatomyositis, characterized by muscle weakness and skin symptoms, is a condition linked to increased morbidity and mortality. […] According to DelveInsight estimates in the latest Dermatomyositis Epidemiology Report, it has affected around 65K adults and 6.5K juveniles in the seven major geographies (the US, Germany, France, Italy, Spain, the UK, and Japan) in 2022. […] Dermatomyositis is rare, and its epidemiology studies on prevalence or occurrence are scarce. The complex pathophysiology of dermatomyositis, coupled with overlapping symptoms with other idiopathic inflammatory myopathies (IIMs), adds intricacy to its epidemiological study. There is a need for new studies to acquire a more comprehensive understanding of the disease epidemiology, encompassing its various types, degrees of severity, and variations across different geographical regions.

• #29

  https://www.healio.com/news/rheumatology/20211008/dermatomyositis-incidence-prevalence-higher-than-previously-reported

  Using the most recent EULAR/American College of Rheumatology criteria, researchers at the Mayo Clinic and the Karolinska Institute determined that the incidence and prevalence of dermatomyositis are higher than previously reported. […] In order to better predict, diagnose and treat it, we need to understand it, starting with epidemiology. […] No previous population-based studies had calculated dermatomyositis incidence, prevalence, or mortality using the new EULAR/ACR 2017 dermatomyositis definition. […] To examine the incidence, prevalence and mortality of dermatomyositis based on the EULAR/ACR criteria, Kronzer and colleagues conducted a retrospective, population-based cohort study within the Rochester Epidemiology Project. […] According to the researchers, who published their findings in Arthritis Care Research, there were 40 cases of verified dermatomyositis, with 29 incident cases in Olmsted County from 1995 to 2019.

• #30 Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort – ACR Meeting Abstracts

  https://acrabstracts.org/abstract/incidence-prevalence-and-mortality-of-dermatomyositis-a-population-based-cohort/

  Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-based Cohort […] Previous epidemiologic studies defined dermatomyositis (DM) using international codes of diseases (ICD) codes or Bohan Peter 1975 criteria, and most were not population-based. Therefore, we aimed to determine the population-based incidence, prevalence, and mortality of DM, all using the new European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2017 DM classification criteria to define patients with DM. […] We identified 40 cases of verified DM meeting at least one of the three DM criteria. Of those, 29 cases were incident DM in the study geographical location from 1995 to 2019 (mean age 57 years, 90% female). […] After age- and sex-adjusting to the US White 2000 population, the overall incidence of DM was 1.1 (95% CI 0.7 to 1.5) per 100,000 person-years, and prevalence was 13 (95% CI 6 to 20) per 100,000. […] This population-based study using validated DM classification criteria found incidence and prevalence on the higher end of previous reports. Though confidence intervals were wide, mortality was significantly elevated for myopathic DM but not for CADM.

• #31

  https://juniperpublishers.com/oroaj/OROAJ.MS.ID.556120.php

  Dermatomyositis (DM) is a rare autoimmune disease predominantly affecting the human skin and muscles, with an estimated prevalence of 1 to 10 cases per 100,000 individuals worldwide. […] Although rare, it affects adults at a prevalence of 1 to 10 cases per million and children at one to 3.2 cases per million. […] In the US, Dermatomyositis has been reported over the years as 0.1 to 1.8 cases per 100,000 person-years, with a trend largely unknown. […] Notably, a nationwide cohort study of US veterans found 679 incident cases of DM, with a median age of 60 years and a higher percentage of women and White patients. […] Recent studies indicate a rising incidence and suggest potential environmental triggers alongside genetic predisposition, manifesting in adults aged 40-60 years, but can also occur in children, affecting more females than males.

• #32 Dermatomyositis Market Insights, Epidemiological Forecast

  https://www.globenewswire.com/news-release/2024/01/22/2813114/28124/en/Dermatomyositis-Market-Insights-Epidemiological-Forecast-to-2032-Advances-Emerging-Therapies-and-Growth-Opportunities.html

  The research publication presents an in-depth analysis of dermatomyositis, including a detailed exploration of epidemiological patterns, diagnostic developments, and therapeutic management. […] The diagnosed prevalence of dermatomyositis is anticipated to rise, reinforcing the need for both existing and emerging treatment modalities. […] The US continues to report the highest number of diagnosed prevalent cases, with a projection of market growth to continue through 2032. […] Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.

• #33 Dermatomyositis Market Size, Competitors & Forecast to 2034

  https://www.researchandmarkets.com/report/dermatomyositis-drug?srsltid=AfmBOoqI5ZOAYoOnOthdmLwUuMJ4ncrvBm1vxaDf18G5NwCeUxys5VHB

  The 7 major dermatomyositis markets reached a value of US$ 192.9 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 278.0 Million by 2034, exhibiting a growth rate (CAGR) of 4.14% during 2023-2034. […] This report provides an exhaustive analysis of the dermatomyositis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. […] According to the report the United States has the largest patient pool for dermatomyositis and also represents the largest market for its treatment. […] Historical, current, and future epidemiology scenario

Zobacz więcej